Research programme: gonadotropin releasing hormone antagonists - Paradigm Therapeutics

Drug Profile

Research programme: gonadotropin releasing hormone antagonists - Paradigm Therapeutics

Alternative Names: PTD 634

Latest Information Update: 13 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Paradigm Therapeutics
  • Developer Takeda Cambridge
  • Class Small molecules
  • Mechanism of Action Gonadotropin releasing hormone inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Prostate cancer

Most Recent Events

  • 08 Nov 2006 PTD 634 has been selected as a clinical development candidate for hormone-dependent prostate cancer
  • 08 Nov 2006 Preclinical data have been added to the pharmacokinetics, adverse events and Cancer pharmacodynamics sections
  • 10 Jan 2005 Amedis Pharmaceuticals has been acquired and merged into Paradigm Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top